Active Surveillance Support Group - Dr. Michael Schweitzer (2 June 2021)
As a medical oncologist, Michael Schweizer, MD, of the Fred Hutch Cancer Center in Seattle, usually sees no patients on active surveillance for low- to favorable intermediate-risk prostate cancer. But this changed when he conducted a study of how apalutamide, a drug used in men with more advanced cancer, on men on AS.
Dr. Schweizer said: “My goal is to help reduce the morbidity and mortality associated with diseases like prostate cancer through developing novel drug therapies.” He plans to study the impact of other meds on men on AS to offer a new way of managing AS.